Hydroxychloroquine (Plaquenil) Toxicity and Recommendations for Screening

John J. Chen, MD, PhD; Ryan M. Tarantola, MD; Christine N. Kay, MD; Vinit B. Mahajan, MD, PhD

Updated by Jason P. Kam, MD,

originally posted: August 30, 2011
updated: September 14, 2016

Chief complaint: Whirling and flashing lights

History of Present Illness

A 57-year-old female presented to the Ophthalmology clinic at UIHC complaining bilateral central photopsias for the past two years. She suffered from Sjogren syndrome and inflammatory arthritis and was currently treated with prednisone and methotrexate. She was previously treated with hydroxychloroquine (Plaquenil) 200mg bid (6.5mg/kg) for 10 years, which was stopped one year prior to presentation.

Past Ocular History: None

Medical History: Sjogren syndrome and inflammatory arthritis, supraventricular tachycardia, anxiety, depression, peptic ulcer disease

Medications: prednisone, methotrexate, amitriptyline, ranitidine, estradiol, tizanidine, diltiazem, Restasis

Allergies: codeine, droperidol

Family History: heart disease, arthritis, cancer

Social History: occasional alcohol but no tobacco or intravenous drug use.

Review of systems:

Blurred vision, halos, dry eye, dry mouth, gastroesophageal reflux, joint pain

OCULAR EXAMINATION

Visual Acuity

Pupils: Reactive to light in each eye from 5 mm in the dark to 2 mm in the light. No relative afferent pupillary defect (RAPD).

Extraocular movements: Full, both eyes (OU)

Confrontation visual fields: Full OU

Intra-ocular pressure

External

Slit Lamp Exam

Dilated Fundus Exam

The optic nerves appeared healthy with a 0.3 cup-to-disc ratio. There was mild paracentral depigmentation of the RPE in the macula that spared the central fovea OU. The vessels and peripheral exam were normal OU (Figure 1). There was no posterior vitreous detachment, retinal tears, or retinal detachments.

Ancillary Tests

Figure 1: Fundus photos demonstrate mild paracentral depigmentation of the RPE that spare the central fovea in both the right (A) and left (B) eyes. Fluorescein angiography shows parafoveal hyperfluorescence OU (C and D).

Figure 1: Fundus photos demonstrate mild paracentral depigmentation of the RPE that spare the central fovea in both the right (A) and left (B) eyes. Fluorescein angiography shows parafoveal hyperfluorescence OU (C and D). (click on image for higher resolution)
Figure 1

Figure 2: 10-2 Humphrey visual fields demonstrate dense paracentral scotomas with decreased foveal sensitivity in both the left (A) and right (B) eyes. (click on image for higher resolution)
Figure 2

Figure 3: Spectral domain optical coherence tomography demonstrates loss of the IS/OS junction and thinning of the outer retina in the parafoveal region (arrows), with preservation of these structures in the fovea of both the right (A) and left (B) eyes. (click on image for higher resolution)
Figure 3

Figure 4: Autofluorescence imaging shows an increase in signal in the parafoveal region of both the right (A) and left (B) eyes. Near-infrared autofluorescence imaging shows increased signal at the fovea OU (C and D). (click on image for higher resolution)
Figure 4

Figure 5: Multifocal electroretinogram. The raw data from both the right (A) and left (B) eyes demonstrate decreased signal centrally and paracentrally. Color schematic of the data demonstrates blunted peak in the right (C) and left (D) eyes. (click on image for higher resolution)
Figure 5

Diagnosis: Hydroxychloroquine-induced retinal toxicity

Discussion

Chloroquine (CQ) and hydroxychloroquine (Plaquenil) (HCQ) have been used for many years, initially for the treatment of malaria but now more commonly for the treatment of inflammatory diseases such as rheumatoid arthritis and lupus [1]. It is now considered for new disease applications in diabetes, heart disease and adjunct cancer therapies [2].

Chloroquine and hydroxychloroquine both belong to the quinolone family and share similar clinical indications and side effects, including retinal toxicity. Chloroquine-induced retinal toxicity was first described in 1959 and the retinal toxic effects of hydroxychloroquine were later described in 1967 [3, 4]. Hydroxychloroquine has significantly less retinal toxicity and has largely replaced chloroquine as a treatment of inflammatory disease. Unfortunately, the retinal damage from these medications is largely irreversible, so it is critical to detect early retinal toxicity in the hopes of limiting the extent of visual loss.

Sign/Symptoms

Ocular manifestations of hydroxychloroquine include corneal verticillata and retinal toxicity. Verticillata are cornea deposits of salts within the corneal epithelium.  This condition does not cause symptoms and is reversible with cessation of the medication. The finding of corneal verticillata bares no correlation with retinal toxicity and is not an indication to stop the medication [1]. The hallmark of hydroxychloroquine toxicity is bilateral pigmentary retinopathy [1]. Patients with early retinal findings are often asymptomatic despite having subtle paracentral scotomas. Later in the disease, patients can develop a bilateral bull's eye maculopathy, characterized by a ring of retinal pigment epithelium (RPE) depigmentation in the macula, sparing the fovea, which is often accompanied by paracentral and central scotomas  [5]. End stage hydroxychloroquine toxicity leads to widespread RPE and retinal atrophy with a loss of central vision, peripheral vision, and night vision. Recent studies have shown that patients of Asian descent develop initial damage in a more peripheral extramacular distribution near the arcades, most frequently in the inferotemporal region with corresponding superonasal field defects. African-American and Hispanic patients display a predominately paravoveal pattern similar to the European subjects [6].

Fundus changes on biomicroscopy, including bull's eye maculopathy, are indicative of fairly advanced hydroxychloroquine-induced retinal toxicity which is largely irreversible despite cessation of the medication. Continued deterioration in visual function can occur after discontinuing hydroxychloroquine, possibly due to slow clearance from the retina and systemically [9, 12]. Screening is important in detecting early retinal toxicity before notable funduscopic changes in order to limit the amount of visual loss. Central vision can be preserved if damage is recognized before there are changes in the retinal pigment epithelium (RPE).

Mechanism

The mechanism of CQ and HCQ is poorly understood. The molecules bind to melanin the RPE causing metabolic changes and toxic effects. The deposits affect the outer retina, photoreceptor layer, and the RPE, but preserve the inner retina.  

Prevalence

Although hydroxychloroquine retinal toxicity is thought to be rare, recent studies suggest it may have a higher prevalence than previously recognized. A large study examining patients with more than 5 years of HCQ use were evaluated with 10-2 visual fields or spectral-domain optical coherence tomography (SD OCT). The overall prevalence of toxicity in this group was 7.5% with a wide variation in daily dose and duration of use. Beyond this point the risk increases sharply to 20% after 20 years [7]. The risk is lower with a lower dose however there is no true safe dosage for longer duration of use.

Another study of 4000 patients found a prevalence of 6.8/1000 patients [8]. Risk factors that increase the chance of hydroxychloroquine retinopathy include daily dosage, cumulative dose, renal or liver disease, age, and previous retinal disease [9]. A daily dose of >6.5mg/kg (ideal body weight) places patients at higher risk, but a daily dose below this level did not preclude the patient from developing toxicity after many years of treatment. A cumulative dose of >1000g of hydroxychloroquine or 460g of chloroquine was likely the largest risk factor, which was typically achieved after 5-7 years of a typical dosage [8, 10]. However, there have been case reports of patients with hydroxychloroquine toxicity as early as 1.9 months after starting treatment [11].

Risk Factors for Retinopathy per 2016 guidelines. Taken from Marmor et al [2]

Daily dose

 

      HCQ

>5.0 mg/kg real weight

      CQ

>2.3 mg/kg real weight

Duration of use

>5 year; no other risk factors

Renal disease

Decreased glomerular filtration rate (GFR)

Concomitant drugs

Tamoxifen use

Macular disease

Increased susceptibility to toxicity

Age

No significant association between age and toxicity risk

Liver Disease

No clear association between liver disease and toxicity

Genetics

No clear association with genetic factors and toxicity

The most critical risk for toxicity is excessive daily dose by weight [6]. Dosage >5.0mg/kg increases the risk of toxicity. Duration of use is also a critical risk factor. Previous recommendations in 2011 noted cumulative dose (daily dose x duration in years) was an indicator of risk, however the most accurate assessment is on the basis of duration of use relative to daily dose per real weight as seen in the figure below. Another change from the 2011 recommendations was that real weight was better than ideal weight for calculating dose and lower risk was achieved with doses 5 mg/kg real weight [6].

 Kaplan Meier curve

Figure 6:  This is a Kaplan Meier curve showing the cumulative risk of retinopathy over time, with different levels of hydroxychloroquine (HCQ) use. When use is between 4.0 and 5.0 mg/kg, the risk is very low within the first 5 to 10 years, but it increases markedly thereafter. Reproduced from Melles and Marmor, 2014 [7]

HCQ is cleared by the kidneys and thus renal disease increases the risk of toxicity. Therefore, both dosage and screening frequency may need to be adjusted. Tamoxifen use (used in breast cancer treatment) increases the risk of toxicity approximately 5 fold) [8]. The mechanism of this linkage is not understood. Patients with underlying retinal disease may be at a higher risk for toxicity, but no specific data has confirmed this. However, maculopathy does makes the implementation and interpretation of screening more difficult.

Screening Guidelines

The American Academy of Ophthalmology (AAO) has recently provided revised recommendations for screening that incorporates new advances in technology allowing for earlier detection of the disease in 2016. 

Guidelines from Marmor et al [2]

 

Timeline

Ancillary Testing

Baseline Screening

Within first year of use

Visual fields and SD OCT if maculopathy is present

Annual Screening

Begin after 5 years of use but sooner if presence of major risk factors

Both HVF 10-2 and SD-OCT; optional testing (as needed): mfERG and/or FAF

Baseline Examination: All patients should have a baseline ophthalmologic examination within the first year of initiating HCQ or CQ therapy with thorough risk factor assessment and fundus examination of the macula to rule out underlying disease. Baseline visual field and SD OCT are recommended if abnormalities are present (e.g. macular lesions, glaucoma, etc) that could affect screening tests.

Annual Screening: The risk of toxicity is rare in the first several years of treatment with HCQ and CQ. In the absence of major risk factors, screening can be postponed for 5 years. Toxicity develops slowly and a yearly exam after year 5 is sufficient.  Earlier screening is recommended for patients with any of the previously mentioned risk factors. Annual screening examinations include biomicroscopy, automated 10-2 visual field and spectral domain optical coherence tomography (SD-OCT) with optional fundus autofluorescence (FAF) and/or multifocal electroretinogram (mfERG) as needed.

Humphrey Visual Field 10-2 is sensitive at detecting subtle paracentral visual field defects and is recommended during all screening visits. SITA testing with pattern deviation plots is recommended. Wider test patterns 24-2 or 30-2 are needed for Asian patients due to the possibility of extra-macular manifestations of toxicity. Large test patterns only test 4 points centrally. There was no mention of testing both 10-2 and large test patterns in the AAO guidelines for Asian patients.

SD-OCT: Unlike time domain optical coherence tomography, SD-OCT has the resolution to detect localized thinning of the retina in the parafoveal region. On SD-OCT, loss or thinning of the parafoveal and perifoveal photoreceptor layer and focal disruption of outer segment laminations are consistent with toxicity [13]. These changes on SD-OCT can be seen before funduscopic abnormalities are present. Wider angle scans or scans across the vascular arcades are important for Asian eyes [6].

Additional useful testing

Multifocal Electroretinogram (mf-ERG): This test allows the detection of localized parafoveal or extramacular depression in early retinopathy [10, 15]. This has similar sensitivity to visual fields and can provide objective confirmation of suspected paracentral field loss.

Fundus Autofluorescence (FAF): Early hydroxychloroquine toxicity can also be detected on autofluorescence as an increased ring of signal within the parafoveal and extramacular regions, which is indicative of photoreceptor dysfunction and RPE dysfunction. More advanced disease will lead to loss of autofluorescence within these regions due to photoreceptor and RPE loss, often with surrounding hyperfluorescence [14].

Tests not recommended: Recent guidelines recommend against biomicroscopy alone, fundus photography, time-domain optical coherence tomography, fluorescein angiography, full-field electroretinogram, Amsler grid, color vision testing, and electro-oculogram [2, 8]. All of these tests are thought to have inadequate sensitivity to detect HCQ/CQ toxicity at an early enough stage to prevent significant vision loss.

In summary, hydroxychloroquine-induced retinal toxicity is likely more prevalent than previously believed. Once thought to be safe at a daily dose of <6.5mg/kg/day [16], newer studies show that many years of hydroxychloroquine treatment at a "safe dose" can still lead to toxicity [6]. Newer guidelines state that daily dose >5mg/kg of real weight/day can lead to toxicity. Retinal toxicity is irreversible and can progress after cessation of hydroxychloroquine, thus early screening is important to limit potential vision loss. Baseline screening and annual screening after five years is recommended.  Ancillary testing modalities, such as SD-OCT, mfERG, and autofluorescence provide sensitive screening tools that complement the 10-2 HVF in detection of early hydroxychloroquine toxicity.

Full clinical history and course

Our patient highlights some of the new findings in hydroxychloroquine retinal toxicity, including the importance of early screening with the appropriate tools described above, the lack of sensitivity of some of the outdated tests, and the potential for worsening despite cessation of the offending medication. When our patient initially presented with haloes and swirling light to an outside provider, she had normal visual acuity and no defects on Amsler grid, color vision testing, or on dilated fundus examination. In addition, her 24-2 HVF one-year prior demonstrated non-specific paracentral changes and was considered full. One year later, a 10-2 HVF was obtained that showed dense paracentral scotomas bilaterally (Figure 2), despite normal visual acuity, Amsler grid, and color vision testing. Upon the detection of the visual field defects, the hydroxychloroquine was stopped. She was taking hydroxychloroquine > 5.0 mg/kg/day with a duration of 10 years with a cumulative dose of 1460g putting her at increased risk for hydroxychloroquine retinal toxicity.

Despite cessation of hydroxychloroquine, one-year follow-up revealed a mild worsening visual acuity to 20/30 OD and 20/25 OS, with new abnormalities on Amsler grid and deficits on color vision testing. Subtle parafoveal RPE depigmentation could be seen on biomicroscopy, which was highlighted by hyperfluorescence on fluorescein angiography (Figure 1). Repeat 10-2 HVF testing demonstrated the dense paracentral scotomas. SD-OCT showed loss of the parafoveal inner/outer segment junction, thinning of the parafoveal outer nuclear layer, and a loss of the normal foveal depression, which is characteristic for hydroxychloroquine retinal toxicity (Figure 3). Autofluorescence imaging showed a ring of hyper-autofluorescence in the parafoveal region corresponding to photoreceptor damage and RPE dysfunction (Figure 4). MfERG demonstrated decreased signal centrally in both eyes (Figure 5). Our patient demonstrates the importance of using the new recommended screening tools for the detection of early hydroxychloroquine toxicity. 10-2 HVF, SD-OCT, autofluorescence, or mfERG might have detected the hydroxychloroquine retinal toxicity on the day of her presenting symptoms and possibly earlier, potentially limiting the amount of visual loss.

Differential Diagnosis

RECOMMENDED SCREENING

  • Baseline screening within 1 year of initiating medication.
  • Annual screening after five years if no risk factors.
  • Biomicroscopy, 10-2 HVF and SD-OCT on annual screening. Ancillary testing optional if no risk factors or other ocular comorbidities on baseline screening however commonly tested.
  • Optional and useful supplemental testing:
    • Fundus auto-fluorescence
    • mfERG.
Early annual screening for patients that have risk factors for developing hydroxychloroquine toxicity.

SIGNS

  • Early signs: visual field defects on 10-2 HVF (usually paracentral), perifoveal and parafoveal thinning of the retina with loss of the inner/outer segment junction on SD-OCT, increased or decreased signal on autofluorescence, central/paracentral ERG depression on mfERG, +/- changes on Amsler grid, +/- subtle RPE changes, +/- decreased color vision
  • Late signs: decreased visual acuity, bull's eye maculopathy, paracentral hyperfluorescence on fluorescein angiography, thinning of the paracentral outer retina on time-domain OCT, 24-2 HVF paracentral VF defects, decreased signal on full-field ERG.

Risk factors:

  • HCQ: daily dosage >5 mg/kg real weight
  • CQ: >2.3 mg/kg real weight
  • Duration >5 years of use
  • No specific cumulative dose
  • Renal disease with decrease glomerular filtration rate.
  • Tamofixen use (concomitant)

SYMPTOMS

  • Decreased vision
  • Photopsias
  • Glare
  • Metamorphopsia
  • Paracentral scotomas
  • Decreased night vision
  • Decreased color vision

TREATMENT

  • No treatment to reverse chloroquine or hydroxychloroquine toxicity.
  • Recommend cessation of the medication, but visual function rarely recovers, especially in the later stages of the disease. Continued deterioration in visual function can occur for a year after discontinuing hydroxychloroquine, possibly due to slow clearance of the medication from the retina and body.

References

  1. Tehrani R, Ostrowski RA, Hariman R, Jay WM: Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 2008, 23(3):201-209.
  2. Marmor MF, Kellner U, Lai TY, Lyons JS, Melles RB, Mieler WF: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 2016, 123:1386-1394.
  3. Hobbs HE, Sorsby A, Freedman A: Retinopathy following chloroquine therapy. Lancet 1959, 2(7101):478-480.
  4. Shearer RV, Dubois EL: Ocular changes induced by long-term hydroxychloroquine (plaquenil) therapy. Am J Ophthalmol 1967, 64(2):245-252.
  5. Gass JDM: Stereoscopic atlas of macular diseases : diagnosis and treatment, 4th edn. St. Louis: Mosby; 1997.
  6. Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 2015;122:110–6.
  7. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014;132:1453–60.
  8. Wolfe F, Marmor MF: Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010, 62(6):775-784.
  9. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF: Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011, 118(2):415-422.
  10. Lyons JS, Severns ML: Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol 2007, 143(5):801-809.
  11. Yam JC, Kwok AK: Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006, 12(4):294-304.
  12. Michaelides M, Stover NB, Francis PJ, Weleber RG: Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol 2011, 129(1):30-39.
  13. Chen E, Brown DM, Benz MS, Fish RH, Wong TP, Kim RY, Major JC: Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign). Clin Ophthalmol 2010, 4:1151-1158.
  14. Kellner U, Renner AB, Tillack H: Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci 2006, 47(8):3531-3538.
  15. Lai TY, Chan WM, Li H, Lai RY, Lam DS: Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol 2005, 140(5):794-807.
  16. Bernstein HN: Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991, 23(8):292-296.

Suggested citation format:

Kam JP. Revision of [Chen JJ, Tarantola, RM, Kay CN, Mahajan VB. Hydroxychloroquine (Plaquenil) Toxicity and Recommendations for Screening. August 30, 2011.] EyeRounds.org. September 14, 2016; Available from: http://EyeRounds.org/cases/139-plaquenil-toxicity.htm.